Ablitech, Inc.

Ablitech, Inc. is a biotechnology company founded in Hattiesburg, Mississippi that specializes in the development and commercialization of platform technologies that heal and protect the human body.[1]

History

Ablitech was co-founded in 2006 by Dr. Lisa Kemp, Dr. Nick Hammond and Dr. Kenneth Malone on technology licensed from The University of Southern Mississippi.

The formation of Ablitech was a direct result of the National Science Foundation program IGERT – an “interdisciplinary training program, educating U.S. Ph.D. scientists and engineers by building on the foundations of their disciplinary knowledge with interdisciplinary training.” [2][3][4]

In 2007, Ablitech received a SBIR Phase I for the development of a bio-transformable drug-eluting coronary stent.[5] Then in 2008 they received another SBIR Phase I for the development of a cancer therapy.[6]

Ablitech received the Mississippi Seed Fund Research and Development investment in 2009 and in 2010.[7] Managed by the Mississippi Technology Alliance, the Mississippi Seed Fund provides high-tech, start-up companies with access to pre-seed financing, early stage risk capital, and product development capital to stimulate and accelerate the development of high-performance, technology-based business ventures in Mississippi.[8]

In 2011, Ablitech received a $2 million grant from the Department of Defense(DoD) to develop a siRNA based therapy for heterotopic ossification.[9]

Location

Ablitech is located at the University of Maryland BioPark. The corporation relocated to Baltimore, Maryland in early 2012.[10]

Research

Ablitech’s signature product, VersadelTM, is a nucleic acid platform delivery technology that “provides a non-toxic, biocompatible method for the systemic and local delivery of antisense DNA and siRNA in the body.” [11]

Awards

References

  1. Ablitech’s Mission Statement. Retrieved 1/07/2011: http://www.ablitech.com.
  2. National Science Foundation. 2007. Young Inventors’ Research Transforms the Marketplace. Retrieved 1/07/2010: http://www.nsf.gov/news/news_summ.jsp?cntn_id=109819&org=DGE&from=news.
  3. Mississippi Gulf Coast Alliance for Economic Development. 2009. Could Ablitech Change Cancer Treatment? Retrieved 1/07/2011: http://www.mscoastaerospace.com/files/q109_newsletter.pdf.
  4. IGERT – About IGERT. Retrieved 1/07/2011: http://www.igert.org/public/about.
  5. Noetic Technologies. 2007. Ablitech, Inc. Receives $100,000 Grant from NSF. Retrieved 1/07/2011: http://www.noetictechnologies.org/news/ablitech_receives_grant.html.
  6. Research Watch. SBIR Phase I: PolyRNA –A Radical Innovation for Healing the Human Body. Retrieved 1/07/2011: http://researchwatch.net/nsf_grants/0810755.
  7. Northway, Wally. 2010. Ablitech receives more ‘Seed’ money from MTA. The Mississippi Business Journal. Retrieved 1/07/2011: http://msbusiness.com/blog/2010/06/ablitech-receives-more-seed-money-from-mta/.
  8. Mississippi Seed Fund. http://www.technologyalliance.ms/seed-fund/.
  9. Ablitech Gets $2M DoD Grant for R&D into Heterotopic Ossification. GEN. Retrieved 10/13/2011:http://www.genengnews.com/gen-news-highlights/ablitech-gets-2m-dod-grant-for-r-d-into-heterotopic-ossification/81245812/.
  10. Sentementes, Gus G. 2012. Mississippi biotech startup moves to Baltimore. Retrieved 12/04/2012: http://articles.baltimoresun.com/2012-02-19/business/bs-bz-ablitech-baltimore-biotech-20120219_1_biotech-clusters-biotech-industry-research-park.
  11. Wbt Innovation Marketplace. 2010. Company Profiles: Ablitech, Inc. Retrieved 10/19/2010: http://www.wbtshowcase.com/wbt/web.nsf/pages/files.html/$file/WBT2011%20Profile%20-%20Ablitech%20Inc.pdf.
  12. Noetic Technologies – invent your future! – Hall of Fame. Retrieved 1/07/2011: http://www.noetictechnologies.com/news/IYFhalloffame.html.
  13. The University of Memphis - FedEx Institute of Technology. 2006. NanoTect Takes Top Prize in Mid-South Business Plan Competition. Retrieved 1/07/2011: http://www.memphis.edu/fedex/releases/2006/4-04-06BusinessFInal.php.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.